Rabies

Dr. Jeanne Bolger to chair Board of Directors of Belgium-based vaccine technology company AstriVax

Retrieved on: 
Monday, September 26, 2022

Dr Jeanne Bolger brings over 35 years of management experience in the pharmaceutical industry to the new Belgium-based vaccine technology company.

Key Points: 
  • Dr Jeanne Bolger brings over 35 years of management experience in the pharmaceutical industry to the new Belgium-based vaccine technology company.
  • With this seed capital and the support of Dr Bolger, AstriVax will continue to build its innovative plug-and-play vaccine platform and bring its first vaccines to the clinical development stage.
  • Leuven, Belgium, 26 September 2022 AstriVax has announced that Dr Jeanne Bolger will chair its Board of Directors as non-executive independent director.
  • As the new Chair of the AstriVax Board, doctor and biotech investor Jeanne Bolger brings extensive experience in the pharmaceutical industry, with management roles across R&D, commercial and business development, and venture investments.

AIM Vaccine Announces Proposed Listing on the Main Board of SEHK

Retrieved on: 
Friday, September 23, 2022

According to CIC, AIM Vaccine is the only China-based vaccine player that has all five proven human vaccine platform technologies worldwide, namely bacterial vaccine technologies, viral vaccine technologies, genetically engineered vaccine technologies, combination vaccine technologies and mRNA vaccine technologies, with at least one approved product or one vaccine candidate at CTA or clinical stages under each platform.

Key Points: 
  • According to CIC, AIM Vaccine is the only China-based vaccine player that has all five proven human vaccine platform technologies worldwide, namely bacterial vaccine technologies, viral vaccine technologies, genetically engineered vaccine technologies, combination vaccine technologies and mRNA vaccine technologies, with at least one approved product or one vaccine candidate at CTA or clinical stages under each platform.
  • AIM Vaccine currently commercializes eight vaccine products against six disease areas, of which the HBV vaccines and human rabies vaccine are its market-leading key commercialized vaccine products.
  • AIM Vaccine acquired Rong'an Bio, AIM Honesty, AIM Kanghuai and AIM Weixin between 2015 and 2017, together with their vaccine products against human rabies, HBV, HAV, mumps and HFRS.
  • AIM Vaccine has leading scientists joining or collaborating with AIM Vaccine to support the Group's vaccine development and manufacturing.

Veterinary Pain Management Market worth $2.5 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, September 22, 2022

In this report, the veterinary pain management market has been segmented by product, application, animal type, end user, and region.

Key Points: 
  • In this report, the veterinary pain management market has been segmented by product, application, animal type, end user, and region.
  • In 2021, the NSAIDs segment accounted for largest share of the veterinary pain management drugs market.
  • The veterinary pain management drugs market is segment into oral, parenteral, and topical on the basis of route of administration.
  • Based on applications, the veterinary pain management market is segmented into joint pain, post-operative pain, cancer, and other applications.

Bavarian Nordic Awarded Ten-Year Contract Amendment valued up to USD 434 million for the Supply of Smallpox and Monkeypox Vaccine to Canada

Retrieved on: 
Tuesday, September 20, 2022

This extends the USD 56 million contract awarded in June 2022 to a total value of up to USD 470 million.

Key Points: 
  • This extends the USD 56 million contract awarded in June 2022 to a total value of up to USD 470 million.
  • Furthermore, a new multi-year contract has been signed with Canadas Department of National Defence (DND) at a value of USD 2 million, in addition to USD 18 million in contract options.
  • Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic, said: With foresight and prioritization, Canada has shown the way to building a robust preparedness for its population.
  • The vaccine is also approved for protection against smallpox and monkeypox in Canada, and as a smallpox vaccine in Europe.

EQS-News: NanoViricides Reports Its Novel Monkeypox Antiviral Could Reach Clinical Status Rapidly

Retrieved on: 
Monday, September 19, 2022

In response to that rapid spread, NanoViricides Inc. (NYSEAMERICAN: NNVC) wants to speed up the timeline on the development of its novel antiviral platform to treat the monkeypox virus.

Key Points: 
  • In response to that rapid spread, NanoViricides Inc. (NYSEAMERICAN: NNVC) wants to speed up the timeline on the development of its novel antiviral platform to treat the monkeypox virus.
  • Heres the companys plan for bringing its monkeypox drug development platform to clinical trials sooner.
  • Having already begun drug development of NV-387-T, its monkeypox drug candidate, NanoViricides reports that its optimistic it can speed up the process to move the antiviral into human clinical trials quickly.
  • NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy.

UK Travel Vaccine Market Report 2022: Increasing Travel and Tourism & Growing Incidences of Infectious Diseases Fuel Sector - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 7, 2022

The "UK Travel Vaccine Market Forecast to 2028 - COVID-19 Impact and Country Analysis By Product and Application" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "UK Travel Vaccine Market Forecast to 2028 - COVID-19 Impact and Country Analysis By Product and Application" report has been added to ResearchAndMarkets.com's offering.
  • Travel vaccines, also called travel immunizations, are shots travelers get before visiting certain areas of the world that help protect them from developing serious illnesses.
  • Based on product, the UK travel vaccines market is segmented into hepatitis A, hepatitis B, meningococcal vaccines, and others.
  • Based on application, the travel vaccine market is segmented into domestic travel and outbound travel.

Arbor Biotechnologies Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in Rare Liver Diseases

Retrieved on: 
Thursday, August 25, 2022

We are looking forward to working with Acuitas, a leading global developer of clinically-validated LNP technology, said Devyn Smith, Ph.D., CEO, Arbor Biotechnologies.

Key Points: 
  • We are looking forward to working with Acuitas, a leading global developer of clinically-validated LNP technology, said Devyn Smith, Ph.D., CEO, Arbor Biotechnologies.
  • Founded in February 2009, Vancouver-based Acuitas Therapeutics ( www.acuitastx.com ) is a private biotechnology company that specializes in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles.
  • Acuitas Therapeutics has agreements in place with several partners to use its proprietary lipid nanotechnology in the development of COVID-19 vaccines.
  • The Acuitas team is currently working on therapeutics focused on addressing cancer, HIV/AIDS, tuberculosis, malaria, rabies, and other serious diseases.

KU Leuven spin-off AstriVax raises € 30 million seed capital to build vaccine platform

Retrieved on: 
Thursday, August 25, 2022

Closing on 30 million, AstriVax has raised the largest amount of seed capital in the history of spin-offs linked to Belgium-based university KU Leuven.

Key Points: 
  • Closing on 30 million, AstriVax has raised the largest amount of seed capital in the history of spin-offs linked to Belgium-based university KU Leuven.
  • Leuven, Belgium, 25 August 2022 Closing on 30 million, AstriVax has raised the largest amount of seed capital in the history of KU Leuven spin-offs.
  • The company will also continue to build its highly innovative, first-in-class plug-and-play vaccine platform based on the ground-breaking work of co-founders Professor Johan Neyts and Kai Dallmeier, PhD, from the KU Leuven Rega Institute.
  • From 2005 to 2021, KU Leuven invested 21.7 million in its spin-off companies, and 1.46 billion of external capital was raised.

Bavarian Nordic Enters Supply Agreement with PAHO to Support Access to Monkeypox Vaccines in Latin America and the Caribbean

Retrieved on: 
Wednesday, August 24, 2022

COPENHAGEN, Denmark, August 24, 2022 Bavarian Nordic A/S (OMX: BAVA) announced today an agreement with the Pan American Health Organization (PAHO) to facilitate equitable access to the Companys monkeypox vaccine for countries in Latin America and the Caribbean.

Key Points: 
  • COPENHAGEN, Denmark, August 24, 2022 Bavarian Nordic A/S (OMX: BAVA) announced today an agreement with the Pan American Health Organization (PAHO) to facilitate equitable access to the Companys monkeypox vaccine for countries in Latin America and the Caribbean.
  • With the agreement, we have now helped to secure access to our vaccine in more than 70 countries globally, representing the vast majority of affected regions outside endemic areas.
  • Bavarian Nordic maintains its guidance for 2022 as this order has already been included in the upgraded financial expectations, as communicated on July 18, 2022.
  • Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines.

Bavarian Nordic Expands Capacity with U.S. Contract Manufacturer for Filling of Smallpox/Monkeypox Vaccines

Retrieved on: 
Thursday, August 18, 2022

By adding the capacity of GRAM to fulfil a significant part of the orders from BARDA, Bavarian Nordic will be able to expedite delivery of vials to the U.S. while also freeing up capacity for other countries.

Key Points: 
  • By adding the capacity of GRAM to fulfil a significant part of the orders from BARDA, Bavarian Nordic will be able to expedite delivery of vials to the U.S. while also freeing up capacity for other countries.
  • With this agreement we will significantly expand our manufacturing capabilities into the United States allowing Bavarian Nordic to meet the growing worldwide demand.
  • Under this contract Bavarian Nordic has produced bulk vaccine, corresponding to approximately 13 million doses.
  • Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines.